Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cuvitru SCIG in Myasthenia Gravis
NCT04728425Phase 2Completed
- Sponsor
- University Health Network
- Start
- Aug 2020
- Primary completion
- Jun 2023
- Modality
- Biologic
- Countries
- 1
01
Overview
A Phase 2 trial of polyvalent human immunoglobulin in myasthenia gravis (MG), sponsored by University Health Network. Started Aug 2020; status: completed.
02
Drugs
polyvalent human immunoglobulin
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT04728425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04728425.